Jennifer Brock

Statistics

Publications

Citations

218

H-Index

Active since

2021

Affiliations

Dana-Farber Cancer Institute(Current)

Brigham and Women's Hospital

Harvard University

Massachusetts General Hospital

Sidney Kimmel Comprehensive Cancer Center

Jennifer Brock is an author at Dana-Farber Cancer Institute specializing in chemotherapy, acute myeloid leukemia treatment, and acute myeloid leukemia therapy.

ORCID

Publications per year

2021–2024

Publications

Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for <i>IDH2</i>-mutated myeloid malignancies

Amir T. Fathi, Haesook T. Kim, Robert J. Soiffer et al. · Blood Advances · 2022 · 58 citations · Full text

Medicine, Hematology, Oncology +17

Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i> -Mutated Acute Myeloid Leukemia

Amir T. Fathi, Haesook T. Kim, Robert J. Soiffer et al. · Clinical Cancer Research · 2023 · 50 citations

Medicine, Hematology, Pharmacology +14

Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active

Jacqueline S. Garcia, Haesook T. Kim, H. Moses Murdock et al. · Blood Advances · 2021 · 46 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML

Jacqueline S. Garcia, Haesook T. Kim, H. Moses Murdock et al. · Blood Advances · 2024 · 43 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial

Vincent T. Ho, Haesook T. Kim, Jennifer Brock et al. · Blood Advances · 2021 · 21 citations · Full text

Pharmacy, Hematology, Immunology +17

1–5 of 5